WallStSmart

Sotera Health Co (SHC)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 3729% more annual revenue ($44.56B vs $1.16B). TMO leads profitability with a 15.0% profit margin vs 6.7%. SHC appears more attractively valued with a PEG of 1.68. SHC earns a higher WallStSmart Score of 62/100 (C+).

SHC

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.5Value: 4.7Quality: 5.8
Piotroski: 6/9

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SHCSignificantly Overvalued (-37.4%)

Margin of Safety

-37.4%

Fair Value

$12.64

Current Price

$13.70

$1.06 premium

UndervaluedFair: $12.64Overvalued
TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SHC1 strengths · Avg: 10.0/10
Operating MarginProfitability
35.7%10/10

Strong operational efficiency at 35.7%

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

SHC4 concerns · Avg: 3.8/10
PEG RatioValuation
1.684/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

EPS GrowthGrowth
1.8%4/10

1.8% earnings growth

Profit MarginProfitability
6.7%3/10

6.7% margin — thin

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : SHC

The strongest argument for SHC centers on Operating Margin.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : SHC

The primary concerns for SHC are PEG Ratio, Revenue Growth, EPS Growth. A P/E of 51.2x leaves little room for execution misses. Debt-to-equity of 4.14 is elevated, increasing financial risk.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

SHC carries more volatility with a beta of 1.88 — expect wider price swings.

TMO is growing revenue faster at 7.2% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SHC scores higher overall (62/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sotera Health Co

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?